[Chemo-endocrine therapy of diffuse carcinoma of the stomach and its clinical evaluation].
Based on experimental study that some human gastric cancers do contain measurable estrogen receptor (ER) and the growth of diffuse carcinoma of the stomach on nude mice depended on sex hormone. Chemo-endocrine therapy after gastrectomy for female patients are starting since 1980.


RESULTS
1) The cumulative 2, 3 and 4 year survival rate in 8 patients with chemo-endocrine therapy (TAM+) revealed significant higher (100%, 80% and 53.4%) than those (59.2%, 23.7% and 0%) in 10 patients with chemotherapy alone (TAM-) after curative gastrectomy. Average disease free interval showed two times longer (32.0 m0) in TAM(+) than those (15.3 m0) in TAM(-). There was no significant on survival rate in both groups of noncurativelly resected patients. 2) Patients with higher ER contents (greater than or equal to 3.0 fmols) have a tendency with favorable prognosis and better response to chemo-endocrine therapy.
D002293:Adenocarcinoma, Scirrhous / Q000188:drug therapy* / Q000401:mortality; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D011960:Receptors, Estrogen / Q000032:analysis; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality; D013629:Tamoxifen / Q000008:administration & dosage*; D005641:Tegafur / Q000008:administration & dosage
D000903:Antibiotics, Antineoplastic; D008937:Mitomycins; D011960:Receptors, Estrogen; D013629:Tamoxifen; D005641:Tegafur; D016685:Mitomycin